Evidence map›Paper›PMID 32854315›Full record

ArticleCells2020

Proteomic Profiling of Extracellular Vesicles Derived from Cerebrospinal Fluid of Alzheimer's Disease Patients: A Pilot Study.

Satoshi Muraoka, Mark P Jedrychowski, Kiran Yanamandra, Seiko Ikezu, Steven P Gygi, Tsuneya Ikezu

Open access · goldAbstract read
In one paragraph

Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it, 188 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Extracellular Vesicles in Tauopathies: Mechanisms and Applications.International journal of molecular sciences · 2026
    Review
  6. Article
  7. bioRxiv : the preprint server for biology · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Satoshi MuraokaDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Mark P JedrychowskiDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Kiran YanamandraAbbvie Inc. Foundational Neuroscience Center, Cambridge, MA 02139, USA.
Seiko IkezuDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Steven P GygiDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Tsuneya IkezuDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Boston University · USHarvard University · USAbbVie (United States) · US

Funding

Exosome-mediated propagation of pathogenic tau proteinRF1AG054199 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2016 to 2021
$5.0M
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer’s diseaseR01AG054672 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BUTOVSKY, OLEG, IKEZU, TSUNEYA · 2017 to 2021
$4.1M
Targeting emerging P2RX7 signaling pathways in animal models of Alzheimer's diseaseR01AG066429 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2020 to 2024
$2.0M
APOE and microglia-mediated progression in tau pathology in ADR01AG054199 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2024 to 2025
$1.4M
Biogenesis of Exosomes, Secretion, and Trafficking in Alzheimer's DiseaseR56AG057469 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HOOK, VIVIAN Y. H, IKEZU, TSUNEYA · 2017 to 2017
$833k
Identification of exosome signature in serum from ALS patientsR21NS104609 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI BERRY, JAMES DALE, BUTOVSKY, OLEG · 2018 to 2019
$543k
NIA NIH HHS R01 AG054199NIA NIH HHS R01 AG054672NIA NIH HHS R01 AG066429NIA NIH HHS R56 AG057469NIA NIH HHS RF1 AG054199NINDS NIH HHS R21 NS104609
6 · The paper itself

Abstract

Pathological hallmarks of Alzheimer's disease (AD) are deposits of amyloid beta (Aβ) and hyper-phosphorylated tau aggregates in brain plaques. Recent studies have highlighted the importance of Aβ and tau-containing extracellular vesicles (EVs) in AD. We therefore examined EVs separated from cerebrospinal fluid (CSF) of AD, mild cognitive impairment (MCI), and control (CTRL) patient samples to profile the protein composition of CSF EV. EV fractions were separated from AD (

Indexed as

Aged, 80 and overAlzheimer DiseaseExtracellular VesiclesFemaleHumansMalePilot ProjectsProteomicsAlzheimer’s diseasebiomarkercerebrospinal fluidextracellular vesiclesproteome

Identifiers

PMID32854315
PMCPMC7565882
OpenAlexW3080420042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.